Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

AIMS: We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Birkeland, Kåre I., Bodegard, Johan, Banerjee, Amitava, Kim, Dae Jung, Norhammar, Anna, Eriksson, Jan W., Thuresson, Marcus, Okami, Suguru, Ha, Kyoung Hwa, Kossack, Nils, Mamza, Jil Billy, Zhang, Ruiqi, Yajima, Toshitaka, Komuro, Issei, Kadowaki, Takashi
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7756303/
https://ncbi.nlm.nih.gov/pubmed/32893440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14189
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados